Functions as a histone acetyltransferase (HAT) to promote transcriptional activation. Has significant histone acetyltransferase activity with core histones (H3 and H4), and also with nucleosome core particles. Inhibits cell-cycle progression and counteracts the mitogenic activity of the adenoviral oncoprotein E1A. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Interacts with SIRT1. Interacts (unsumoylated form) with NR2C1; the interaction promotes transactivation activity. Interacts with EP300, CREBBP and DDX17. Interacts with NCOA1 and NCOA3. Component of a large chromatin remodeling complex, at least composed of MYSM1, KAT2B/PCAF, RBM10 and KIF11/TRIP5. Interacts with NR2C2 (hypophosphorylated and unsumoylated form); the interaction promotes the transactivation activity of NR2C2. Binds to HTLV-1 Tax. Interacts with and acetylates HIV-1 Tat. Interacts with KLF1; the interaction does not acetylate KLF1 and there is no enhancement of its transactivational activity. Interacts with NFE4. Interacts with MECOM. Interacts with E2F1; the interaction acetylates E2F1 augmenting its DNA-binding and transcriptional activity. Ubiquitously expressed but most abundant in heart and skeletal muscle. Belongs to the GCN5 family. Note: This description may include information from UniProtKB.
Protein type: Acetyltransferase; Nuclear receptor co-regulator; EC 126.96.36.199
Cellular Component: kinetochore; nucleoplasm; I band; PCAF complex; chromatin remodeling complex; actomyosin; nucleus; A band
Biological Process: transcription initiation from RNA polymerase II promoter; Notch signaling pathway; negative regulation of cyclin-dependent protein kinase activity; transcription from RNA polymerase I promoter; chromatin remodeling; negative regulation of cell proliferation; protein amino acid acetylation; cellular response to insulin stimulus; virus-host interaction; positive regulation of transcription from RNA polymerase II promoter; gene expression; transcription initiation from RNA polymerase I promoter; cell cycle arrest; peptidyl-lysine acetylation; N-terminal peptidyl-lysine acetylation
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.